Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...
Monthly injection with tezepelumab helped 90% of patients with severe asthma reduce intake of daily steroid tablets. The corresponding study was published in The Lancet Respiratory Medicine. “In this ...
Forbes contributors publish independent expert analyses and insights. AI researcher working with the UN and others to drive social change. Dec 01, 2025, 07:08am EST Hacker. A man in a hoodie with a ...
An injected antibody reduced daily steroid pills in most people, and eliminated asthma attacks and the need for any pills at all in more than half of the people who received it The treatment, called ...
People with severe asthma sometimes rely on daily steroid pills, which raise the risk of diabetes, infections and bone problems. Now, a study supports the idea that a monthly antibody injection is a ...
A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with long-term side effects. More than half of the participants who had received the ...
A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with long-term side effects. More than half of the participants who had received the ...
A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid medications, according to a new phase 3b clinical trial published in The Lancet ...
What Is Voyxact, and Why Does It Matter? Voyxact (sibeprenlimab-szsi) is a new medicine approved by the FDA to lower protein levels in urine for adults with a kidney condition called primary ...
A new addition to Fresenius Kabi’s anti-infective portfolio, Dalbavancin for Injection is indicated for acute bacterial skin and skin structure infections and approved for single-dose regimen use only ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback